Psychiatric disorders and hepatitis C treated with direct-acting antivirals in a French reference center


Psychiatric disorders and hepatitis C treated with direct-acting antivirals in a French reference center


Michel Doffoel1*, Florence Ernwein1, Frédéric Chaffraix1, Simona Tripon1, Jean-Philippe Lang1, Anais Lang1, Lucile Haumesser2, Robert Bader3, Dominique Paya4, Maude Royant1, Aurélie Velay-Rusch5, Martine Tebacher6, Nicolas Meyer2, Thomas Baumert7, François Habersetzer8 and Laurence Lalanne9,10

1Service expert de lutte contre les hépatites virales d’alsace (SELHVA) Pôle hépato-digestif, Nouvel hôpital civil, Hôpitaux universitaires, Strasbourg, France. 2Groupe méthode en recherche clinique, Pôle de santé publique au travail, Hôpitaux universitaires, Strasbourg, France. 3Service d’hépato gastroentérologie, Groupement hospitalier régional Mulhouse sud alsace, Mulhouse, France. 4Pharmacie, Hôpitaux universitaires, Strasbourg, France. 5Laboratoire de Virologie, Hôpitaux universitaires, Strasbourg, France. 6Centre régional de pharmacovigilance grand est, Hôpitaux universitaires, Strasbourg, France. 7Institut de Recherche sur Maladies Virales et Hépatiques, Inserm U1110, Université de Strasbourg, Strasbourg, Institut Universitaire de France, Paris, France; 8Service d’hépato gastroentérologie, Pôle hépato-digestif, Nouvel hôpital civil, Hôpitaux universitaires, Strasbourg, France. 9Département de Psychiatrie et d’Addictologie et Fédération de Médecine Translationnelle de Strasbourg (FMTS), Hôpitaux universitaires, Strasbourg, France. 10Institute for research on viral and hepatic diseases, Inserm U1110, University of Strasbourg, Strasbourg, University Institute of France, Paris, France.


HCV can cause psychiatric disorders. It is crucial to re-evaluate them with direct-acting antiviral treatment (DDAs), since the interferon-based treatments of the past were capable of causing identical psychiatric adverse effects. A system of multidisciplinary team (MDT) meetings was implemented in France in December 2014 in regional reference centers with the aim of controlling the prescription and administration of these new treatments, along with optimizing how the patients undergoing these treatments are followed up. Our study sought to compare the characteristics and type of medical care received for chronic hepatitis C in patients with (PSY+ group) and without (PSY- group) psychiatric disorders using data from MDT meetings in the Alsace area of France collected from 2015 to 2019.

All included patients were mono-infected and treated with DAAs in successive rounds between 2015 and 2019, as per recommendations from the French Hepatology Society. We compared the two groups (PSY+ and PSY-) based on 21 variables regarding the characteristics and medical care of hepatitis C.

Psychiatric disorders were observed in 15% of patients. On multivariate analysis, a positive correlation was found between them and drug use (OR: 2.35; 95%CI: 1.40-3.98; p=0.001), excessive alcohol consumption (OR: 1.92; 95%CI: 0.98-3.69; p=0.05), smoking (OR: 1.81; 95%CI: 1.09-2.98; p=0.02), and incidence of drug interactions (OR: 3.94; 95%CI: 2.15-7.17; p <0.001). The only negative correlation found was with pangenotypic DAA administration (OR: 0.55; 95%CI: 0.32-0.92; p=0.02). SVR 12 was 98.05% in the PSY+ group, not significantly different from that of the PSY- group.

All in all, the psychiatric disorders observed in patients suffering from chronic hepatitis C are primarily associated with using psycho-active substances, with no impact on SVR 12 rates.

Lay summary

The psychiatric disorders observed in patients suffering from chronic hepatitis C treated with direct-acting antivirals are primarily associated with drug use, excessive alcohol consumption and tobacco consumption. They increase the incidence of drug interactions. They have no impact on virological healing.

Highlights:

  • 15% of patients with HCV monoinfection treated with direct-acting antivirals were suffering from psychiatric disorders.
  • Psychiatric disorders were associated with drug use.
  • They were also associated with other psycho-active substances (alcohol and tobacco).
  • They increased the incidence of drug interactions.
  • They have no impact on sustained virological response.

Keywords: hepatitis C, psychiatric disorders, multidisciplinary team meetings, direct-acting antivirals.

Free Full-text PDF


How to cite this article:
Michel Doffoel, Florence Ernwein, Frédéric Chaffraix, Simona Tripon, Jean-Philippe Lang, Anais Lang, Lucile Haumesser, Robert Bader, Dominique Paya, Maude Royant, Aurélie Velay-Rusch, Martine Tebacher, Nicolas Meyer, Thomas Baumert, François Habersetzer, Laurence Lalanne. Psychiatric disorders and hepatitis C treated with direct-acting antivirals in a French reference center. Open Journal of Gastroenterology and Hepatology, 2021, 4:55. DOI: 10.28933/ojgh-2021-10-1205


References:

1. Wilkinson J, Radkowski M, Laskus T. Hepatitis C virus neuroinvasion: identification of infected cells. J Virol 2009; 83: 1312–1319.
https://doi.org/10.1128/JVI.01890-08
2. Pflugrad H, Meyer GJ, Dirks M, Raab P, Tryc AB, Goldbecker A, et al. (2016). Cerebral mi-croglia activation in hepatitis C virus infection correlates to cognitive dysfunction. J Viral Hepat 2016; 23: 348–357. https://doi.org/10.1111/jvh.12496
3. Schaefer M, Capuron L, Friebe A, Diez-Quevedo C, Robaeys G, Neri S, et al. Hepatitis C infection, antiviral treatment and mental health: a European expert consensus state-ment. J Hepatol 2012; 57: 1379–1390.https://doi.org/10.1016/j.jhep.2012.07.037
4. Negro F, Forton D, Craxì A, Sulkowski MS, Feld JJ, Manns MP (2015). Extrahepatic mor-bidity and mortality of chronic hepatitis C. Gas-troenterology 2015; 149: 1345–1360.
https://doi.org/10.1053/j.gastro.2015.08.035
5. Sène D, Limal N, Cacoub P. (2004). Hepatitis C virus-associated extrahepatic manifestations: a review. Metab Brain Dis 2004, 19: 357–381. https://doi.org/10.1023/b:mebr.0000043982.17294.9b
6. Pol S, Vallet-Pichard A, Hermine O (2018). Ex-trahepatic cancers and chronic HCV infection. Nat Rev Gastroenterol Hepatol 2018;15: 283–290. https://doi.org/10.1038/nrgastro.2017.172
7. 7. Hughes E, Bassi S, Gilbody S, Bland M, Martin F. (2016). Prevalence of HIV, hepatitis B, and hepatitis C in people with severe mental ill-ness: a systematic review and meta-analysis. Lancet Psychiatry 2016; 3: 40–48.https://doi.org/10.1016/S2215-0366(15)00357-0
8. 8. Mackesy-Amiti ME, Donenberg GR, Ouellet LJ. Prevalence of psychiatric disorders among young injection drug users. Alcohol Depend 2012; 124: 70-78.
doi:10.1016/j.drugalcdep.2011.12.012
9. Dinwiddie SH, Reich T, Cloninger CR. Psychia-tric comorbidity and suicidality among intrave-nous drug users. J Clin Psychiatry 1992; 53 : 364-369.
10. Gibbie TM, Hides LM, Cotton SM, Lubman DI, Aitken C, Hellard M. The relationship between personality disorders and mental health sub-stance use severity and quality of life among injecting drug users. Med J Aust 2011; 195: S16-21.
https://doi.org/10.5694/j.1326-5377.2011.tb03260.x
11. Peirce JM, Kolodner K, Brooner RK, Kidorf MS. Traumatic event re-exposure in injecting drug users. J Urban Health 2012; 89: 117-128. https://doi.org/10.1007/s11524-011-9619-9
12. Adinolfi LE, Nevola R, Lus G, Restivo L, Guer-rera B, Romano C, et al. Chronic hepatitis C vi-rus infection and neurological and psychiatric disorders: An overview. World J Gastroenterol 2015; 21: 2269-80.https://doi.org/10.3748/wjg.v21.i8.2269
13. Rolland B, Bailly F, Cutarella C, Drevon O, Car-rieri P, Darque A, et al. Hépatite C en milieu psychiatrique: un réservoir oublié? L’Encephale 2021; 47: 181–184.
https://doi.org/10.1016/j.encep.2020.03.003
14. Direction générale de la Santé. Lettre d’instruction relative à l’organisation de la prise en charge de l’hépatite C par les nouveaux anti-viraux d’action directe (NAAD). Paris: DGS; 2014. 5 p.
http://www.chru-stras-bourg.fr/sites/default/files/u122/Lettre_d_instruction_hepatite_C_NAAD_29_dec_2014.pdf
15. Ministère des Affaires sociales et de la Santé. Instruction N° DGOS/PF2/DGS/SP2/PP2/DSS/ 1C/2016/246 du 28 juillet 2016 relative à l’organisation de la prise en charge de l’hépatite C par les nouveaux antiviraux d’action directe (NAAD). 2016. 14 p. http://www.chru-stras-bourg.fr/sites/default/files/u122/Circulaire_du_28_juillet_2016_pec_des_AAD.pdf
16. Ministère des Solidarités et de la Santé. InstructionN° DGOS/PF2/DGS/SP2/DSS/1C/2017/246
du 3 août 2017 relative à l’élargissement de la prise en charge par l’assurance maladie du trai-tement de l’hépatite C par les nouveaux agents antiviraux d’action directe (AAD) à tous les stades de fibrose hépatique pour les indica-tions prévues par l’autorisation de mise sur le marché et à la limitation de la tenue d’une réu-nion de concertation pluridisciplinaire pour les initiations de traitement à des situations particu-lières listées. 2017. 9 p.https://solidarites-sante.gouv.fr/fichiers/bo/2017/17-08/ste_20170008_0000_0046.pdf
17. Thelliez B. La révolution passe (enfin) par l’officine. Le Pharmacien de France 2018; 1330 http://www.lepharmaciendefrance.fr/actualite-web/la-revolution-passe-enfin-par-lofficine
18. Haute Autorité de Santé. Hépatite C : prise en charge simplifiée chez l’adulte. Recomman- da-tions de bonne pratique. Internet.. Saint Denis La Plaine: HAS; 2019.
https://www.has-sante.fr/jcms/c_2911891/fr/hepatite-c-prise-en-charge-simplifiee-chez-l-adulte
19. Société Française d’Hépatologie. Recomman- dations AFEF sur la prise en charge des hépa-tites virales C. 2015, 2016, 2017 et 2019. Paris: AFEF.https://afef.asso.fr/recommandations/recommandations-afef/
20. Société Française d’Hépatologie. Recomman- dations AFEF sur la prise en charge des hépa-tites virales C. Fiche RCP hépatites virales C. Paris : AFEF 2017.https://afef.asso.fr/wp-content/uploads/2018/06/Fiche-RCP-juillet-2017-afef.pdf
21. Jauffret-Roustide M, Pillonel J, Weill-Barillet L, Léon L, Le Strat Y, Brunet S, et al. Estimation de la séroprévalence du VIH et de l’hépatite C chez les usagers de drogues en France. Pre-miers résultats de l’enquête ANRS-Coquelicot 2011. Bull Epidémiol Hebd. 2013 ; 39-40: 504-509.http://beh.santepubliquefrance.fr/beh/2013/39-40/2013_39-40_2.html
22. Drinking guidelines: General population. Interna-tional Alliance for Responsable Drinking (IARD); 2019https://iard.org/science-resources/detail/Drinking-Guidelines-General-Population
23. Organisation de la prise en charge thérapeu-tique et du suivi des personnes usagères de drogues infectées par le virus de l’hépatite C. In : Prise en charge thérapeutique et suivi de l’ensemble des personnes infectées par le virus de l’hépatite C. Rapport de recommandations 2016. EDP Sciences, Paris, 2016, p 13-30.
24. Goldner EM, Lusted A, Roerecke M, Rehm J, F.B. Prevalence of Axis-1 psychiatric (with focus on depression and anxiety) disorder and symp-tomatology among non-medical prescription opioid users in substance use treatment: sys-tematic review and meta-analyses. Addict Be-hav 2014; 39: 520–531.https://doi.org/10.1016/j.addbeh.2013.11.022
25. Dinwiddie SH, Shicker L, Newman T. Preva-lence of hepatitis C among psychiatric patients in the public sector. Am J Psychiatry 2003; 160: 172–174.https://doi.org/10.1176/appi.ajp.160.1.172
26. Dervaux A, Laqueille X. Comorbidités psychia- triques du tabagisme. In : Traité d’Addictologie, Reynaud M Ed. Cachan, France : Lavoisier Mé-decine, 2016 ; p 585-589.https://www.cairn.info/traite-d-addictologie–9782257206503-page-585.htm
27. Luger T M, Suls J, Van der Weg MW. How ro-bust is the association between smoking and depression in adults? A meta-analysis using linear mixed-effects models. Addict Behav 2014; 39: 1418–1429.https://doi.org/10.1016/j.addbeh.2014.05.011
28. Lasser K, Boyd JW, Woolhandler S, Himmelstein DU, McCormick D, Bor DH. (2000). Smoking and mental illness: A population-based prevalence study. JAMA 2000; 284:2606–2610.https://doi.org/10.1001/jama.284.20.2606
29. Pawlotsky JM, Negro F, Aghemo A, Beren- guer M, Dalgard O, Dusheiko G, et al. EASL recommendations on treatment of hepatitis C: Final update of the series. J Hepatol 2020;73: 1170-1218.


Terms of Use/Privacy Policy/ Disclaimer/ Other Policies:
You agree that by using our site, you have read, understood, and agreed to be bound by all of our terms of use/privacy policy/ disclaimer/ other policies (click here for details).



This work and its PDF file(s) are licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.